3 days ago · The announcement came as Novo Nordisk announced it was expanding its offer for cash-paying patients to access to its Wegovy (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, …

2 days ago · Novo Nordisk has acquired the rights to UBT251, a new obesity and diabetes drug, for up to $2 billion. The drug, developed by United Bio-Technology, combines GLP-1, GIP, and …

3 days ago · Novo Nordisk has decided that it wants its own triple agonist, and is willing to hand over $200 million upfront to United Laboratories’ subsidiary United Biotechnology.

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24.

3 days ago · Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company currently is the leading …

4 days ago · Novo Nordisk just agreed to shell out up to $2 billion for the global rights to a Chinese weight-loss drug—and the market wasn’t thrilled. The company’s U.S.-listed shares …

3 days ago · Novo Nordisk stock slipped 2% to 75.33, while Lilly shares rose 3.3% to 864.90. 15% Body Weight Over 12 Weeks United Biotechnology recently wrapped a Phase 1 study of …

3 days ago · Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the health care system is improving.

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese pharmaceutical company The United Bio-Technology Co., as it …

2 days ago · Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an …